Article
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jun 2011
Yang Ming, Xie Wanling, Mostaghel Elahe, Nakabayashi Mari, Werner Lillian, Sun Tong, Pomerantz Mark, Freedman Matthew, Ross Robert, Regan Meredith, Sharifi Nima, Figg William Douglas, Balk Steven, Brown Myles, Taplin Mary-Ellen, Oh William K, Lee Gwo-Shu Mary, Kantoff Philip W
Abstract excerpt
PURPOSE: Androgen deprivation therapy (ADT), an important treatment for advanced prostate cancer, is highly variable in its effectiveness. We hypothesized that genetic variants of androgen transporter genes, SLCO2B1 and SLCO1B3, may determine time to progression on ADT. PATIENTS AND METHODS: A co...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
